Intermittent Antibody-Based Combination Therapy Removes Alloantibodies and Achieves Indefinite Heart Transplant Survival in Presensitized Recipients | Zendy

Hina Shariff | Zendy; Yakup Tanriver | Zendy; Kathryn Brown | Zendy; Lucy Meader | Zendy; Roseanna Greenlaw | Zendy; Nizam Mamode | Zendy; Stipo Jurčević | Zendy

Open Access

Intermittent Antibody-Based Combination Therapy Removes Alloantibodies and Achieves Indefinite Heart Transplant Survival in Presensitized Recipients

Author(s) -

Hina Shariff,

Yakup Tanriver,

Kathryn Brown,

Lucy Meader,

Roseanna Greenlaw,

Nizam Mamode,

Stipo Jurčević

Publication year - 2010

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/tp.0b013e3181e228bd

Subject(s) - medicine , elispot , cd8 , heart transplantation , combination therapy , immunology , transplantation , t cell , cd154 , splenocyte , cell therapy , antibody , immune system , cytotoxic t cell , cell , cd40 , biology , biochemistry , in vitro , genetics

It is well established that primed/memory T cells play a critical role in heart transplant rejection. This contributes to the challenges faced in the transplant clinic because current treatments that are efficient in controlling naïve T cell alloresponses have limited efficacy on primed T cell responders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research